SAN FRANCISCO Guided by lawyers at Morrison & Foerster, Israeli pharmaceutical company Kamada raised $51.6 million in its initial public offering.
The company, which specializes in protein purification technology, offered 5.6 million shares at $9.25 in the IPO, which closed Wednesday. MoFo partners Bruce Mann and Andrew Thorpe, both based in San Francisco, represented Kamada. A Davis Polk & Wardwell team led by New York partner Michael Kaplan advised the underwriters.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
